UNSPSC 51312611: Etintidine hydrochloride

This classification denotes a histamine-2 receptor antagonist with the molecular formula C12H16N6S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T20BD719DD, chemically known as guanidine, n-cyano-n-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-n-2-propynyl-, monohydrochloride but more generally known as etintidine hydrochloride, which bears US NIH Compound Identifier 150171. Most nations, for tariff and trade purposes, schedule etintidine hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, ETINTIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etintidine hydrochloride bears US NLM identifiers UMLS ID C0955885 and NCI Concept Code C81155. SMILES: CC1C(NC[NH]1)CSCCNC(=NC#N)NCC#C.CL.

UNSPSC 51312611 Etintidine hydrochloride is a Commodity code representing a specific pharmaceutical product, but the recent state and local opportunities tagged under it do not actually solicit etintidine. Instead, the code shows activity for broader pharmaceutical procurement—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program development. State and local governments use this code tier to buy finished pharmaceuticals and related health commodities through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The work involves vendor qualification, product compliance certification (cGMP, DSCSA, FDA requirements), pricing negotiation across multiple tiers (manufacturers, wholesalers, end-use facilities), and logistics coordination including quarterly or ongoing delivery to health department and community health facilities.

The most recent activity appears in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, response due July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs serving self-insured employee health plans. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations require vendor compliance with drug supply chain, manufacturing, and quality assurance standards; the MMCAP RFP emphasizes pricing competitiveness (75 percent of evaluation weight) and mandatory relationships with authorized wholesalers.